✦ LIBER ✦

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

✍ Scribed by Mikkael A. Sekeres; Hagop Kantarjian; Pierre Fenaux; Pamela Becker; Adam Boruchov; Agnes Guerci-Bresler; Kuolung Hu; Janet Franklin; Yow-Ming C. Wang; Dietmar Berger

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 355 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25545

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cause of death in patients with lower-ri

Cause of death in patients with lower-risk myelodysplastic syndrome

✍ Farshid Dayyani; Anthony P. Conley; Sara S. Strom; William Stevenson; Jorge E. C 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB

Inefficacy of intravenous immunoglobulin

Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome

✍ Dr. Guido Finazzi; Piero Bellavita; Anna Falanga; Piera Viero; Tiziano Barbui 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 404 KB 👁 2 views

A randomized study of 2 dose levels of i

A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

✍ Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Farhad Ravandi; Gautam Bo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 1 views

## Abstract ## BACKGROUND: Clofarabine is a nucleoside analog with activity in myeloid malignancies. Experience in myelodysplastic syndrome (MDS) is limited. ## METHODS: The goal of this study was to evaluate the activity and safety of 2 different doses (15 mg/m^2^ vs 30 mg/m^2^ daily × 5 days)

Predictors and outcome of acute kidney i

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

✍ Amit Lahoti; Hagop Kantarjian; Abdulla K. Salahudeen; Farhad Ravandi; Jorge E. C 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 1 views

Intravenous itraconazole for prophylaxis

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy

✍ Gloria N. Mattiuzzi; Hagop Kantarjian; Susan O'Brien; Dimitrios P. Kontoyiannis; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## BACKGROUND Systemic fungal infections remain the leading cause of mortality in patients with newly diagnosed acute myelogenous leukemia (AML) and high‐risk myelodysplastic syndrome (MDS). The objective of the current study was to determine whether intravenous itraconazole (I.V. ITRA

Prognostic relevance of achieving cytoge

Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy

✍ Sebastian Balleisen; Andrea Kuendgen; Barbara Hildebrandt; Rainer Haas; Ulrich G 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 249 KB

Cytogenetic findings at diagnosis have influence on prognosis in patients with acute myelogenous leukaemia (AML) or MDS who undergo induction chemotherapy. Assessment of remission and treatment decisions are based on cytological findings. We analyzed the prognostic impact of cytogenetic remission st